The Lancet
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
✓ Free legal copy found
Accepted manuscript, hosted by eprints.gla.ac.uk
This is the peer-reviewed text the journal accepted, before its typesetting. The content matches the published paper; the layout and page numbers differ.
Read it free at eprints.gla.ac.uk →Licence: CC BY-SA
Other free copies
DOI: 10.1016/s0140-6736(18)30207-1 · Publisher: Elsevier BV